Periodic Reporting for period 1 - NASHTARGET (Validation of a new drug target in non-alcoholic steatohepatitis)

The prevalence of metabolic liver disease is rising sharply, mainly driven by the causal connections between obesity, diabetes, and non-alcoholic steatohepatitis (NASH). In the absence of approved treatments, NASH represents a clear unmet medical need and an enormous economic...